298 related articles for article (PubMed ID: 19105706)
1. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Vogel VG
Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
[TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
3. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
6. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
7. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
9. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Dickler MN; Norton L
Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen-receptor modulators.
Cosman F
Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
[TBL] [Abstract][Full Text] [Related]
12. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
13. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
14. SERMs for the treatment and prevention of breast cancer.
Swaby RF; Sharma CG; Jordan VC
Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
[TBL] [Abstract][Full Text] [Related]
15. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
16. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.
Legault C; Maki PM; Resnick SM; Coker L; Hogan P; Bevers TB; Shumaker SA
J Clin Oncol; 2009 Nov; 27(31):5144-52. PubMed ID: 19770382
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
